GENZYME ANNOUNCES PROPOSAL TO INCREASE ITS OFFER TO ACQUIRE ANORMED TO $13.50 PER SHARE IN CASH

Genzyme Corporation announced that it has informed the Board of Directors of AnorMED Inc. that it is prepared to increase its offer to acquire all outstanding shares of AnorMED to US $13.50 per share, or approximately $580 million, contingent upon AnorMED executing a support agreement with Genzyme. This proposal represents a premium of 12.5 percent over the purchase price proposed by Millennium Pharmaceuticals on September 26, 2006.

WebWire (http://webwire.com/ViewPressRel.asp?SESSIONID=&aId=21861)